Processa Pharmaceuticals Launches Website to Raise Awareness and Inform Patients of Ongoing Phase 2b Study of PCS499
Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Lipoid Necrobiosis Study HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces today…